BioCryst Pharmaceuticals (BCRX) late Thursday appointed Jon P. Stonehouse, its chief executive officer as chief financial officer and principal accounting officer on an interim basis, after Anthony Doyle stepped down from the positions earlier this week.
BioCryst also said Doyle will continue to work with the company through May 31 as a paid consultant assisting with the transition.
It also has hired the former CFO at a publicly traded biotechnology company to help with its financial reporting during the search for a permanent CFO. The identity of the executive was not revealed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.